OKN-007 (Oklahoma nitrone-007), a novel anti-glioma nitrone-based agent, resulted in a significant decrease in hypoxia (HIF-1α) and cell proliferation (MIB-1), an increase of apoptosis (cleaved caspase 3), while showed mixed results about angiogenesis, such as decreased micro-vessel density (MVD) but not of VEGF, and no effect on cell differentiation (CA-IX) [110] (Table 6). The gene discussed is VEGFA; the disease is central nervous system cancer.